ArticleHeliyon2024
CAE-ResVGG FusionNet: A Feature Extraction Framework Integrating Convolutional Autoencoders and Transfer Learning for Immature White Blood Cells in Acute Myeloid Leukemia.
Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Artificial inteligence and datasets for leukemia diagnosis: A scoping review of machine lerning and deep learning approaches.MethodsX · 2025Review
- Data Augmentation and Synthetic Data Generation in Rare Disease Research: A Scoping Review.Medical sciences (Basel, Switzerland) · 2025Article
- Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute myeloid leukemia (AML) is a highly aggressive cancer form that affects myeloid cells, leading to the excessive growth of immature white blood cells (WBCs) in both bone marrow and peripheral blood. Timely AML detection is crucial for effective treatment and patient well-being. Currently, AML diagnosis relies on the manual recognition of immature WBCs through peripheral blood smear analysis, which is time-consuming, prone to errors, and subject to inter-observers' variation. This study aimed to develop a computer-aided diagnostic framework for AML, called "CAE-ResVGG FusionNet", that precisely identifies and classifies immature WBCs into their respective subtypes. The proposed framework leverages an integrated approach, by combining a convolutional autoencoder (CAE) with finely tuned adaptations of the VGG19 and ResNet50 architectures to extract features from CAE-derived embeddings. The process begins with a binary classification model distinguishing between mature and immature WBCs followed by a multiclassifier further classifying immature cells into four subtypes: myeloblasts, monoblasts, erythroblasts, and promyelocytes. The CAE-ResVGG FusionNet workflow comprises four primary stages, including data preprocessing, feature extraction, classification, and validation. The preprocessing phase involves applying data augmentation methods using geometric transformations and synthetic image generation using the CAE to address imbalance in the WBC distribution. Feature extraction involves image embedding and transfer learning, where CAE-derived image representations are used by a custom integrated model of VGG19 and ResNet50 pretrained models. The classification phase employs a weighted ensemble approach that leverages VGG19 and ResNet50, where the optimal weighting parameters are selected using a grid search. The model performance was assessed during the validation phase using the overall accuracy, precision, and sensitivity, while the area under the receiver characteristic curve (AUC) was used to evaluate the model's discriminatory capability. The proposed framework exhibited notable results, achieving an average accuracy of 99.9%, sensitivity of 91.7%, and precision of 98.8%. The model demonstrated exceptional discriminatory ability, as evidenced by an AUC of 99.6%. Significantly, the proposed system outperformed previous methods, indicating its superior diagnostic ability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.